Journal article
Early experience with UGN-101 for the treatment of upper tract urothelial cancer – A multicenter evaluation of practice patterns and outcomes
Urologic oncology, Vol.41(3), pp.147.e15-147.e21
03/2023
DOI: 10.1016/j.urolonc.2022.10.029
Abstract
UGN-101 is a novel delivery system for intracavitary treatment of upper tract urothelial cancer (UTUC). UGN-101 was approved based on a pivotal trial for small volume residual low-grade UTUC. Our aim was to report our experience with UGN-101 in a more heterogenous and real-world setting.
We performed a retrospective review of all UGN-101 cases from 15 institutions with a focus on practice patterns, efficacy, and adverse effects. We include UGN-101 utilization in both the chemoablative and adjuvant setting.
There were a total 136 renal units treated from 132 patients. The majority of cases were biopsy proven low-grade UTUC. Practice patterns varied considerably - the most common administration technique was antegrade instillation via a percutaneous nephrostomy. When utilized in the adjuvant setting, 69% of patients were disease free at the time of their first endoscopic evaluation, while in the chemoablative setting, 37% were endoscopically clear on the first evaluation (P < 0.001). Complete response was higher in patients with smaller tumor size prior to UGN-101 induction; low volume (<1 cm) residual disease was associated with a 70% complete response, similar to disease free rate at first endoscopic evaluation when UGN-101 was used in the adjuvant setting. The use of maintenance doses of UGN-101 was reported in 27% of cases. The overall incidence of new onset, clinically significant ureteral stenosis was 23%.
This study represents the largest review of patients treated with UGN-101 and can serve as a basis of ongoing hypotheses regarding treatment with UGN-101 for UTUC.
Details
- Title: Subtitle
- Early experience with UGN-101 for the treatment of upper tract urothelial cancer – A multicenter evaluation of practice patterns and outcomes
- Creators
- Solomon L. Woldu - The University of Texas Southwestern Medical CenterCraig Labbate - The University of Texas MD Anderson Cancer CenterKatie S. Murray - University of MissouriKyle Rose - Moffitt Cancer CenterWade Sexton - Moffitt Cancer CenterIsamu Tachibana - Indiana UniversityHristos Kaimakliotis - Indiana UniversityJoseph Jacob - State University of New York Upstate Medical Center, Syracuse, NYRian Dickstein - University of Maryland Medical CenterJennifer LinehanAlan Nieder - Mount Sinai Medical CenterMarc A. Bjurlin - Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NCMitchell Humphreys - Mayo Clinic Cancer Center, Phoenix, AZSaum Ghodoussipour - Rutgers Cancer Institute of New Jersey, New Brunswick, NJMarcus L. Quek - Loyola University Medical CenterMichael O'Donnell - University of IowaBrian H. Eisner - Massachusetts General HospitalAdam S. Feldman - Massachusetts General HospitalSurena F. Matin - The University of Texas MD Anderson Cancer CenterYair Lotan - The University of Texas Southwestern Medical Center
- Resource Type
- Journal article
- Publication Details
- Urologic oncology, Vol.41(3), pp.147.e15-147.e21
- DOI
- 10.1016/j.urolonc.2022.10.029
- ISSN
- 1078-1439
- eISSN
- 1873-2496
- Publisher
- Elsevier Inc
- Language
- English
- Electronic publication date
- 11/2022
- Date published
- 03/2023
- Academic Unit
- Urology
- Record Identifier
- 9984353408702771
Metrics
15 Record Views